Inclusion Criteria:

- Adult patients, >/= 18 years of age

- Histologically or cytologically confirmed locally advanced or metastatic (IIIB/IV)
non-squamous non-small cell lung cancer (NSCLC) which is routinely evaluated in
clinical practice according to RECIST criteria

- EGFR mutation-positive disease according to local laboratory testing

- Patients on treatment with Tarceva monotherapy as first-line treatment according to
the physician's usual practice

Exclusion Criteria:

- Prior systemic therapy for advanced NSCLC. The administration of neoadjuvant or
adjuvant chemotherapy is allowed as long as it was finalized >6 months prior to
receiving Tarceva

- Participation in another clinical study

- Patients could have received radiotherapy as long as the irradiated lesion was not
the only lesion for evaluating response and a long as the radiotherapy was completed
before initiating Tarceva treatment